Extendryl

Extendryl

a trademark for a fixed-combination nasal decongestant drug containing an adrenergic (phenylephrine hydrochloride), an antihistaminic (chlorpheniramine maleate), and an anticholinergic (methscopolamine nitrate).
References in periodicals archive ?
The planned acquisition includes Zytopic for atopic dermatitis, a type of itchy and scaly skin rash; Coraz for seborrhoeic dermatitis, a skin condition where flaky white or yellow scales appear on the scalp or inside the ear; Xylarid for hemorrhoids; Zinx for cough and cold; Extendryl for congestion; Liquadd for attention deficit disorder; Akurza for psoriasis, a disease that causes thick, red skin with flaky scales; Breeze pads for acne and Levall for cough.
Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral for the treatment of Xerostomia, Akurza and Xyralid dermatology products, and the Zinx, Extendryl, and Levall families of products for relief of symptoms associated with a range of acute respiratory diseases.
a specialty pharmaceutical company formed to drive high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, has released revenue guidance for the remainder of calendar year 2006 and for 2007, projecting significant revenue increases through sales growth of its FDA-authorized prescription drug products, including Extendryl and other brands.
The revenue forecasts are based on a number of assumptions and other factors, including historical sales of Extendryl and Levall, projected demand for the newly FDA-cleared product Aquoral and our ability to increase our commissioned sales force.
Auriga is targeting the multibillion-dollar cold, respiratory and allergy markets through its Extendryl and Levall families of prescription drug products.
Since last year, Auriga has bolstered its product portfolio following the milestone acquisitions of exclusive distribution rights to Extendryl, Levall and Aquoral.
This improvement is primarily related to a favorable shift in the 2007 product mix toward developed products without royalties as well as reduced royalties on both Extendryl and Levall in accordance with their license agreements.